Skip to content
10-K

Annual Report

CRESCENT BIOPHARMA, INC. CBIO

0001628280-26-011983

← back to feed
Filed
Feb 26, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Feb 23, 2026 27.56M sh
Capex FY 2025 · Dec 31, 2025 $919K
Capex FY 2025 · Dec 31, 2024 $0
Operating Cash Flow FY 2025 · Dec 31, 2025 −$71.53M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$6.27M
Cash And Equivalents FY 2025 · Dec 31, 2025 $213.19M
Cash And Equivalents restated FY 2025 · Dec 31, 2024 $34.77M
Stockholders Equity FY 2025 · Dec 31, 2025 $203.01M
Stockholders Equity restated FY 2025 · Dec 31, 2024 −$15.48M
Stockholders Equity FY 2025 · Sep 19, 2024 $0
Current Liabilities FY 2025 · Dec 31, 2025 $36.07M
Current Liabilities restated FY 2025 · Dec 31, 2024 $9.61M
Total Liabilities FY 2025 · Dec 31, 2025 $37.28M
Total Liabilities restated FY 2025 · Dec 31, 2024 $47.1M
Current Assets FY 2025 · Dec 31, 2025 $236.66M
Current Assets restated FY 2025 · Dec 31, 2024 $34.8M
Total Assets FY 2025 · Dec 31, 2025 $240.29M
Total Assets restated FY 2025 · Dec 31, 2024 $35.62M
Rd Expense FY 2025 · Dec 31, 2025 $138.09M
Rd Expense FY 2025 · Dec 31, 2024 $14.03M
Net Income FY 2025 · Dec 31, 2025 −$153.94M
Net Income FY 2025 · Dec 31, 2024 −$17.87M
Operating Income FY 2025 · Dec 31, 2025 −$152.63M
Operating Income FY 2025 · Dec 31, 2024 −$17.19M
Revenue FY 2025 · Dec 31, 2025 $10.84M
Revenue FY 2025 · Dec 31, 2024 $0